CClinicalTrials.gg
Sign In
CompletedNCT02449941Updated Dec 6, 2016

Helicobacter Pylori and Proton Pump Inhibitor

An observational study in Helicobacter Infections, sponsored by Asan Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-12-06.

Sponsored by Asan Medical Center · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
30
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Read the detailed description

Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during, and after using PPI.

02

Conditions studied

  • Helicobacter Infections

Keywords

  • Stomach Neoplasms
  • proton pump inhibitor
  • endoscopic submucosal dissection
  • Helicobacter pylori
  • Gastritis, Atrophic
03

In context

Helicobacter Infections

186 studies on the registry are indexed under Helicobacter Infections; 32 are open to participants now.

This study's enrollment of 30 is below the median of 180 across 47 observational studies indexed under Helicobacter Infections.

Browse Helicobacter Infections studies →

Lead sponsor

Asan Medical Center is the lead sponsor of 562 studies on the registry; 71 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Sample size will be determined based on the analysis the distribution rate of HP at first 30 patients.

Inclusion criteria

  1. Patients who are indicated to endoscopic resection due to gastric neoplasm
  2. Aged between 19 to 65 years
  3. Informed consent

Exclusion criteria

Exclusion Criteria:

  1. Previous history of HP eradication
  2. Previous history of PPI use within 6 months
  3. No HP infection
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Helicobacter pylori(HP) positive

    Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).

    Drug: PPI (proton pump inhibitor)

Interventions

  • DrugPPI (proton pump inhibitor)

    1. Pre ESD (endoscopic submucosal dissection) * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori * Use of PPI for 2 months 2. Post ESD 1 (After 2 months) * Assess the distribution of helicobacter pylori after using PPI. * Stop of PPI 3. Post ESD 2 (After 4 months) * Assess the distribution of helicobacter pylori after stop of PPI.

    Also known as: pantoprazole, lansoprazole, dexlansoprazole, rabeprazole

06

What researchers measure

Primary outcomes

  1. Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor

    Time frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.

Secondary outcomes

  1. Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach

    Time frame: Change in the distribution of Helicobacter Pylori(HP) at 4 months.

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Songpa-gu 138-736, Korea, Republic of
08

References and documents

Publications

  • Gong EJ, Kim DH, Ahn JY, Na HK, Jung KW, Lee JH, Choi KD, Song HJ, Lee GH, Jung HY, Park Y, Kim MJ. Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy. Digestion. 2020;101(3):279-286. doi: 10.1159/000499424. Epub 2019 May 8. PubMed 31067538 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02449941
Lead sponsor
Asan Medical Center
Responsible party
Ji Yong Ahn (Professor, Asan Medical Center) — Principal investigator
First posted
May 21, 2015
Start date
Mar 2014
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Dec 6, 2016

Study contacts

Ji Yong Ahn, Professor
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Helicobacter Infections→

Other studies from this sponsor

Asan Medical Center

Start the discussion